FDA Approves ANI Pharma's Generic Everolimus Tablets
(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) said Wednesday that it received final FDA approval for Everolimus Tablets for Oral Suspension, a generic version of Novartis' Afinitor Disperz, which is approved for certain conditions associated with tuberous sclerosis complex (TSC).
IQVIA data for July 2026 showed annual US sales of Everolimus Tablets for Oral Suspension at approximately $123 million.
ANI CEO Nikhil Lalwani said the company remains on track to launch at least 15 new generic products in 2026.
ANI Pharma shares closed at $77.91 on Tuesday, down 1.19%.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.